These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 30097256)
1. Enhanced treatment of lung cancer by metronomic therapy with oral pemetrexed. Park K J Control Release; 2018 Aug; 284():250-251. PubMed ID: 30097256 [No Abstract] [Full Text] [Related]
2. Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. Mahmud F; Jeon OC; Alam F; Maharjan R; Choi JU; Park J; Lee S; Park JW; Lee DS; Byun Y J Control Release; 2018 Aug; 284():160-170. PubMed ID: 29908222 [TBL] [Abstract][Full Text] [Related]
3. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013 [TBL] [Abstract][Full Text] [Related]
4. [Pemetrexed for Treatment of Nonsquamous Non-Small-Cell Lung Cancer]. Omori Y; Enatsu S Gan To Kagaku Ryoho; 2018 Nov; 45(11):1609-1613. PubMed ID: 30449848 [TBL] [Abstract][Full Text] [Related]
5. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis. Zhong A; Xiong X; Shi M; Xu H Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy. Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156 [TBL] [Abstract][Full Text] [Related]
8. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396 [TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management. Mahmud F; Chung SW; Alam F; Choi JU; Kim SW; Kim IS; Kim SY; Lee DS; Byun Y J Control Release; 2017 Mar; 249():42-52. PubMed ID: 28093298 [TBL] [Abstract][Full Text] [Related]
18. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003). Hata A; Katakami N; Hattori Y; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S Cancer Chemother Pharmacol; 2017 Apr; 79(4):689-695. PubMed ID: 28280972 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]